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http://www.biomedcentral.com/1471-2121/14/41RESEARCH ARTICLE Open AccessRetinoic acid has different effects on UCP1
expression in mouse and human adipocytes
Maria Murholm1,2†, Marie S Isidor1,2†, Astrid L Basse1,2, Sally Winther1, Cathrine Sørensen1, Jonas Skovgaard-Petersen1,
Maja M Nielsen1, Aina S Hansen1, Bjørn Quistorff2 and Jacob B Hansen1*Abstract
Background: Increased adipose thermogenesis is being considered as a strategy aimed at preventing or reversing
obesity. Thus, regulation of the uncoupling protein 1 (UCP1) gene in human adipocytes is of significant interest.
Retinoic acid (RA), the carboxylic acid form of vitamin A, displays agonist activity toward several nuclear hormone
receptors, including RA receptors (RARs) and peroxisome proliferator-activated receptor δ (PPARδ). Moreover, RA is a
potent positive regulator of UCP1 expression in mouse adipocytes.
Results: The effects of all-trans RA (ATRA) on UCP1 gene expression in models of mouse and human adipocyte
differentiation were investigated. ATRA induced UCP1 expression in all mouse white and brown adipocytes, but
inhibited or had no effect on UCP1 expression in human adipocyte cell lines and primary human white adipocytes.
Experiments with various RAR agonists and a RAR antagonist in mouse cells demonstrated that the stimulatory
effect of ATRA on UCP1 gene expression was indeed mediated by RARs. Consistently, a PPARδ agonist was without
effect. Moreover, the ATRA-mediated induction of UCP1 expression in mouse adipocytes was independent of PPARγ
coactivator-1α.
Conclusions: UCP1 expression is differently affected by ATRA in mouse and human adipocytes. ATRA induces UCP1
expression in mouse adipocytes through activation of RARs, whereas expression of UCP1 in human adipocytes is
not increased by exposure to ATRA.
Keywords: Adipogenesis, ATRA, Brown adipocyte, UCP1, White adipocyteBackground
Mammals have two types of fat, white and brown
adipose tissue (WAT and BAT, respectively), that carry
out essentially opposite functions in whole body energy
metabolism [1,2]. White adipocytes are specialized in
energy storage and their content of triglyceride constitutes
the largest energy reserve of the body. Contrary, brown
adipocytes have a high capacity for energy dissipation
through adaptive thermogenesis due to the presence of the
brown adipocyte-specific uncoupling protein 1 (UCP1) in
the inner membrane of the abundant mitochondria. BAT
has been shown to counteract obesity and is important
for rodents to defend their body temperature in response
to prolonged cold exposure [1]. Brown-like adipocytes* Correspondence: jacob.hansen@bio.ku.dk
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reproduction in any medium, provided the orexpressing UCP1 appear in some rodent WAT depots
after cold exposure or treatment with β-adrenergic agonists
[3,4]. Recent studies have suggested a negative correlation
between body mass index and the amount of active BAT in
humans [5]. Strategies aiming at increasing levels of UCP1
in WAT have become of interest as reduced expression of
brown adipocyte-enriched genes in WAT is associated with
obesity and type 2 diabetes in humans [6-8].
Retinoic acid (RA) is a derivative of vitamin A that affects
cellular growth, differentiation and apoptosis in various
embryonic and adult tissues [9,10]. All-trans RA (ATRA)
has been reported being an agonist for multiple nuclear
receptors, including RA receptors (RARs) [11,12], peroxi-
some proliferator-activated receptor δ (PPARδ, also desig-
nated PPARβ) [13], testicular orphan receptor 4 (TR4) [14]
and chicken ovalbumin upstream promoter transcription
factor II (COUP-TFII) [15]. It has been proposed that
PPARδ mediates part of the metabolic effects of ATRA
[16]. Additionally, ATRA has been shown to regulate geneal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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believed that most effects of ATRA are mediated by RARs
that upon heterodimerization with retinoid X receptors
control gene expression through binding to RA response
elements in regulatory regions of target genes [9,18].
High concentrations of ATRA inhibit differentiation of
3T3-L1 white preadipocytes and C3H10T½ mesenchymal
stem cells [19-21], whereas low concentrations have been
shown to stimulate white adipogenesis of Ob1771 cells
[22]. The inhibition of adipogenesis by ATRA is mediated
by RARs and is linked to suppression of CCAAT/en-
hancer-binding protein β activity and induction of anti-
adipogenic genes [19,21,23].
The UCP1 gene of mice, rats and humans contains
RAR-responsive elements in its enhancer region and ATRA
has been shown to promote UCP1 expression and oxidative
metabolism in cultured rodent adipocytes [24-31]. More-
over, treatment of mice with ATRA causes increased
expression of UCP1 in WATand BAT [17,28,31,32].
In the present study we compared the response of mouse
and human preadipocytes and mature adipocytes to ATRA,
with emphasis on the effects on differentiation and UCP1
expression. In addition, we have studied the importance
of RARs, PPARδ and PGC-1α for the regulation of UCP1
expression by ATRA. We find that ATRA increases UCP1
expression in all mouse adipocyte models studied, including
3T3-L1 white adipocytes, and that this induction is medi-
ated by RARs and is independent of PPARδ and PGC-1α.
Finally, ATRA does not increase UCP1 expression in any
of the human adipocytes examined in this study.Results
Exposure of differentiating mouse adipocytes to ATRA
increases UCP1 expression
In order to examine the effects of ATRA on differenti-
ating mouse adipocytes, we exposed four cell models
of adipogenesis to a range of ATRA concentrations
(10 nM to 10 μM) throughout the course of the differenti-
ation process, i.e. between days −2 (the time of confluence)
and 8 (designated chronic exposure). Gene expression was
analyzed at day 8. We estimated the degree of differenti-
ation by measuring mRNA levels of the adipocyte marker
gene fatty acid-binding protein 4 (FABP4, also designated
aP2). Expression of the brown fat-specific UCP1 gene was
determined at both the mRNA and protein levels, and the
expression of RARβ was used to estimate the degree of
activation of RARs, as the RARβ gene is responsive to
retinoids [33,34]. The cells used were 3T3-L1 preadipocytes,
wild-type (WT) mouse embryo fibroblasts (MEFs) and the
mesenchymal stem cell line C3H10T½ as models of
white adipocyte differentiation [35,36], and MEFs lacking
a functional retinoblastoma gene (Rb−/−) as a model of
brown adipocyte differentiation [35].RARβ expression increased dose-dependently in response
to treatment with ATRA in 3T3-L1, WT MEFs and
C3H10T½ cells, whereas the same pattern was not ob-
served in Rb−/− MEFs (Figure 1A-D). A dose-dependent
reduction of FABP4 expression was seen in WT MEFs,
C3H10T½ and Rb−/− MEFs, whereas only the highest
level of ATRA (10 μM) blocked adipose conversion of
3T3-L1 cells (Figure 1A-D). ATRA in intermediate con-
centrations (1 μM in 3T3-L1, 0.1 μM and 1 μM in WT
MEF-derived adipocytes and 0.1 μM in C3H10T½ and
Rb−/− adipocytes) induced expression of UCP1 at both
mRNA and protein levels, with a maximum fold induction
of mRNA levels of 4, 18, 4 and 3 in 3T3-L1, WT MEF-
derived, C3H10T½ and Rb−/− MEF-derived adipocytes,
respectively (Figure 1A-E). Although ATRA in intermedi-
ate concentrations induced expression of UCP1 in all
cases, the absolute level of UCP1 varied substantially be-
tween the cell models, being highest in Rb−/− adipocytes
and lowest in WT MEF-derived adipocytes. In summary,
chronic exposure to high concentrations of ATRA inhibits
adipocyte differentiation, whereas intermediate concentra-
tions cause increased expression of UCP1, even in 3T3-L1
white adipocytes.
Exposing mature mouse adipocytes to ATRA enhances
expression of UCP1
In addition to the chronic exposure to ATRA described
above, we also analyzed the effects of exposing mature
mouse adipocytes to ATRA at day 8 (designated acute
exposure). In this case, we used a fixed concentration of
ATRA (1 μM) and harvested RNA and protein after 24 h
(i.e. at day 9). Expression of UCP1 and RARβ increased in
response to ATRA compared to vehicle in WT and Rb−/−
MEF-derived and C3H10T½ adipocytes, but not in 3T3-
L1 adipocytes, with UCP1 mRNA levels increasing 15-,
4.6- and 2.5-fold, respectively, in the former three cell
models (Figure 2A-D). Levels of UCP1 protein mirrored
the levels of UCP1 mRNA (Figure 2E). FABP4 mRNA levels
were slightly reduced by the acute exposure to ATRA in
MEF-derived adipocytes, but not in 3T3-L1 and C3H10T½
adipocytes.
RARs mediate the effects of ATRA
As ATRA has been shown to bind and activate a range
of nuclear receptors, we wished to identify the relevant
targets of ATRA mediating the effects observed above.
Therefore, we treated WT MEFs with TTNPB, a pan-RAR
agonist not displaying agonist activity toward PPARδ [13],
using the two same experimental setups described above.
Both chronic application of TTNPB (Figure 3A) and acute
application of TTNPB to mature adipocytes (Figure 3B)
resulted in expression patterns of FABP4, UCP1 and RARβ
similar to those observed upon treatment with ATRA
(see Figures 1 and 2). Expression levels of UCP1 reached
Figure 1 Chronic treatment with ATRA induces UCP1 expression in differentiating mouse adipocytes. 3T3-L1 cells, WT MEFs,
C3H10T½ cells and Rb−/− MEFs were treated with ATRA from day −2 to day 8 in the concentrations indicated. Total RNA and protein were
harvested at day 8 and analyzed by RT-qPCR and immunoblotting, respectively. Relative mRNA expression levels of FABP4, UCP1 and RARβ
were determined by normalization to expression levels of TATA-binding protein (TBP). (A) 3T3-L1 cells. (B) WT MEFs. (C) C3H10T½.
(D) Rb−/− MEFs. (E) Protein levels of UCP1 with GAPDH used as a loading control. (A-D) Data represents mean + SEM (n = 3). *, p < 0.05
versus vehicle-treated cells.
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(1 nM TTNPB) (Figure 3A) and 6-fold after treatment of
mature adipocytes with 1 nM TTNPB for 24 h (Figure 3B).
Next, we investigated if the pan-RAR antagonist BMS493
could inhibit the UCP1-inducing effects of ATRA. When
applied chronically during differentiation (Figure 3C) and
acutely to mature adipocytes (Figure 3D), BMS493 elimi-
nated and blunted, respectively, the enhanced expression
of UCP1 caused by ATRA. These results strongly suggest
that the action of ATRA is mediated through RARs.
To delineate which of the three RAR isoforms that
are responsible for the upregulation of UCP1, we used
three RAR subtype-selective agonists: AM580 (RARα
selective); tazarotene (RARβ/γ selective) and CD1530
(RARγ selective). All three agonists caused an induction
of UCP1 expression when administered chronically to dif-
ferentiating WT MEFs (Figure 4A). AM580 and tazarotene
induced the highest fold increase in UCP1 expression
(11- and 8-fold, respectively). A dose-dependent increase
in RARβ mRNA and a reduction of FABP4 mRNA levelswere observed for all three agonists (Figure 4A). Notably,
as AM580 has a 30-40-fold selectivity for RARα compared
to RARβ and RARγ [37], the observation that 10 nM
AM580 was sufficient to increase UCP1 levels suggests
that activation of RARα is sufficient (Figure 4A). However,
tazarotene and CD1530 were also able to increase UCP1
levels despite a low affinity for RARα, indicating that acti-
vation of any RAR subtype is capable of increasing UCP1
expression in mouse adipocytes.
When the three agonists were acutely supplemented to
mature WT MEF-derived adipocytes, UCP1 mRNA levels
were significantly induced after 24 h, with AM580 and
tazarotene displaying the most potent effect (Figure 4B).
PPARδ activation does not increase UCP1 expression
in MEF-derived white adipocytes
As mentioned, ATRA can bind to PPARδ and increase its
transcriptional activity [13,38], and activation of PPARδ
is believed to regulate thermogenic gene expression in
adipose tissue [39,40]. To determine if activation of PPARδ
Figure 2 Acute exposure of mature mouse adipocytes to ATRA induces UCP1 expression. ATRA (1 μM) was supplemented at day 8. Total
RNA and protein were harvested after 24 h and analyzed by RT-qPCR and immunoblotting, respectively. Relative mRNA expression levels of
FABP4, UCP1 and RARβ were determined by normalization to levels of TBP. (A) 3T3-L1. (B) WT MEFs. (C) C3H10T½. (D) Rb−/− MEFs. (E) Protein
levels of UCP1 with GAPDH used as a loading control. (A-D) Data represents mean + SEM (n = 3). *, p < 0.05 versus vehicle-treated cells at day 9.
Murholm et al. BMC Cell Biology 2013, 14:41 Page 4 of 13
http://www.biomedcentral.com/1471-2121/14/41mimics the effects observed with ATRA, we exposed WT
MEFs to the PPARδ agonist GW501516 either during dif-
ferentiation (Figure 5A) or acutely to mature adipocytes
(Figure 5B). GW501516 did not change either UCP1 or
FABP4 mRNA levels in either case (Figure 5A and B). The
PPARδ target gene adipose differentiation-related protein
(ADRP, also designated adipophilin and perilipin 2) [41]
was significantly upregulated when GW501516 was added
chronically (Figure 5A).The effects of ATRA on UCP1 expression is not dependent
on PGC-1α
PGC-1α is a metabolically regulated transcriptional
coactivator that is known to induce UCP1 levels in adipo-
cytes and to interact with RARα in an ATRA-dependent
manner [42]. To investigate whether PGC-1α is required
for the ATRA-mediated effects, we compared immortalized
brown preadipocyte cell lines from WT and PGC-1α-defi-
cient mice [43]. ATRA was supplemented either chronically
Figure 3 (See legend on next page.)
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Figure 3 TTNPB mimics and BMS493 inhibits the effects of ATRA in WT MEFs. Total RNA was harvested at the indicated days (day 8 in
panels A and C) and analyzed by RT-qPCR. Relative mRNA expression levels of FABP4, UCP1 and RARβ were determined by normalization to TBP.
(A) TTNPB was supplemented to differentiating cells from day −2 to day 8 at the concentrations indicated. (B) TTNPB (1 nM) was acutely
supplemented to mature adipocytes (day 8) and harvested after 24 h. (C) Treatment with BMS493 (1 μM) and/or ATRA (1 μM) from day −2 to day
8. (D) Acute supplementation of BMS493 (1 μM) and/or ATRA (1 μM) to mature adipocytes from day 8 and harvested after 24 h. Data represents
mean + SEM (n = 3). *, p < 0.05 versus vehicle-treated cells. ▲, p < 0.05 versus ATRA-treated cells.
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UCP1 expression was increased at intermediate concen-
trations of ATRA in the chronically treated PGC-1α+/+
and PGC-1α−/− adipocytes (Figure 6A). The highest level
of UCP1 was observed with 0.1 μM ATRA in WT adipo-
cytes (3.5-fold above vehicle), but with 1 μM ATRA in
PGC-1α−/− adipocytes (17-fold above vehicle). Of notice,
basal expression of UCP1 was lower in PGC-1α-deficient
fat cells (Figure 6A and B). A minor decrease in FABP4
expression with 10 μM ATRA and a dose-dependent in-
crease in RARβ expression were observed (Figure 6A).
Exposing mature PGC-1α+/+ and PGC-1α−/− adipocytes
to 1 μM ATRA elicited significant induction of UCP1Figure 4 RAR subtype-selective ligands induce UCP1 expression in W
indicated days (panel B) and analyzed by RT-qPCR. Relative mRNA express
normalization to TBP. (A) RAR subtype-selective ligands AM580, tazarotene
concentrations indicated. (B) RAR subtype-selective ligands AM580 (1 μM),
mature adipocytes from day 8 and harvested after 24 h. Data represents mafter 24 h (Figure 6B). Thus, enhanced expression of
UCP1 caused by ATRA does not require PGC-1α.
ATRA inhibits human adipocyte differentiation in a
dose-dependent manner and does not increase UCP1
expression
To investigate if chronic treatment with ATRA had the
same effects on human adipocytes as observed with mouse
adipocytes, we exposed the human white preadipocyte
cell line SGBS [44], human multipotent adipose-derived
stem cells (hMADS) [45,46] and primary human white
preadipocytes to various concentrations of ATRA during
differentiation (Figure 7A-C). The human adipocytes wereT MEFs. Total RNA was harvested at day 8 (panel A) or at the
ion levels of FABP4, UCP1 and RARβ were determined by
and CD1530 were supplemented from day −2 to day 8 at the
tazarotene (1 μM) and CD1530 (1 μM) were acutely supplemented to
ean + SEM (n = 3). *, p < 0.05 versus vehicle-treated cells.
Figure 5 Activation of PPARδ in WT MEFs does not increase
UCP1 expression. Total RNA was harvested at day 8 (panel A) or at
the indicated days (panel B) and analyzed by RT-qPCR. Relative
mRNA expression levels of FABP4, UCP1 and ADRP were determined
by normalization to TBP. (A) Treatment with the PPARδ agonist
GW501516 (1 μM) from day −2 to day 8. (B) GW501516 (1 μM) was
acutely supplemented to mature adipocytes from day 8 and
harvested after 24 h. Data represents mean + SEM (n = 3). *, p < 0.05
versus vehicle-treated cells.
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mouse adipocytes, as their morphological differentiation
into adipocytes was substantially slower. High concentra-
tions of ATRA inhibited differentiation of SGBS (10 μM),
hMADS (10 μM) and primary preadipocytes (1 and 10 μM),
as estimated by expression of FABP4 mRNA. RARβ ex-
pression increased dose-dependently in all three cell
models (Figure 7A-C). Interestingly, the low basal UCP1
mRNA levels in SGBS and hMADS adipocytes did not in-
crease at any concentration of ATRA compared with
vehicle-treated cells and were lower with 1 and 10 μM
ATRA (Figure 7A and B). Notably, FABP4 expression was
not affected by 1 μM ATRA. Basal expression of UCP1 inprimary preadipocytes exposed to ATRA during differenti-
ation was strongly inhibited by ATRA, an inhibition ob-
served even at the lowest concentration used (10 nM)
(Figure 7C). Levels of UCP1 protein were determined in
SGBS and hMADS adipocytes and confirmed that ATRA
did not increase UCP1 levels (Figure 7D). Acute exposure
of mature adipocytes to 1 μM ATRA did not result in any
significant changes in mRNA levels of FABP4 or mRNA
and protein levels of UCP1 compared to vehicle treatment
in SGBS, hMADS or primary cells (Figure 8). Basal UCP1
mRNA expression was undetectable in primary human
white adipocytes from another donor and expression
remained undetectable after treatment with ATRA
(data not shown). In summary, ATRA does not increase
expression of UCP1 in the human adipocyte models
studied here.
Discussion
In this study, we report the effects of ATRA on differenti-
ation and UCP1 expression in various mouse and human
adipocytes. We find that high concentrations of ATRA
inhibit mouse and human adipogenesis, whereas lower
concentrations enhance UCP1 expression in mouse, but
not in human, adipocytes. In addition, we show that the
effects of ATRA are mediated by RARs and not by PPARδ
or other ATRA-activated nuclear receptors. Moreover,
the enhanced expression of UCP1 in response to ATRA
is independent of PGC-1α.
Adipocyte and adipose tissue function are impacted by
ATRA [47,48]. Expression of UCP1 is reduced in BAT of
mice fed vitamin A-depleted feed [17,49] and exogenous
ATRA enhances expression of UCP1 in both WAT and
BAT of mice and rats [16,17,28,32,49,50]. Expression of
UCP1 is induced by ATRA in primary brown adipocytes
from mice and rats as well as in mouse brown adipocyte
cell lines [24,26,28,29,51-53]. Moreover, UCP1 expression
is strongly induced in MEF-derived white adipocytes [31].
Contrary, ATRA has been reported not to induce expres-
sion of UCP1 in mature 3T3-L1 adipocytes and mouse
primary white adipocytes [16,30,54]. Exposure to ATRA
leads to activation of p38 mitogen-activated protein kinase
(MAPK), an activation that is required for full induction
of UCP1 expression by ATRA [29,31].
ATRA has been reported to activate three nuclear
receptors besides RARs, namely PPARδ, COUP-TFII and
TR4. The induction of UCP1 observed in the mouse cells
applied in this study is unlikely to be mediated by COUP-
TFII and TR4, as the app. EC50 of ATRA are 20 μM [15]
and 24 μM [14], respectively, which is 20 to 240 times
higher than the concentrations inducing UCP1. Although
the EC50 of ATRA for PPARδ is much lower than for
COUP-TFII and TR4 (app. 200 nM) [13], PPARδ is not
mediating the effects of ATRA either. Firstly, the RAR
agonist TTNPB mimics the effects of ATRA (see Figure 3),
Figure 6 ATRA enhances UCP1 expression independent of PGC-1α. Total RNA was harvested at day 8 (panel A) or at the indicated days
(panel B) and analyzed by RT-qPCR. Relative mRNA expression levels of FABP4, UCP1 and RARβ were determined by normalization to TBP.
(A) ATRA was supplemented to differentiating PGC-1α+/+ and PGC-1α−/− brown preadipocytes from day −2 to day 8 at the concentrations
indicated. (B) ATRA (1 μM) was acutely supplemented to mature PGC-1α+/+ and PGC-1α−/− adipocytes from day 8 and harvested after 24 h.
Data represents mean + SEM (n = 3). *, p < 0.05 versus vehicle-treated cells.
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PPARδ agonist does not enhance expression of UCP1 (see
Figure 5). Thirdly, a RAR antagonist attenuates the effects
of ATRA (see Figure 3). In this study, we have not
addressed the potential involvement of nongenomic effects
of ATRA, e.g. activation of p38 MAPK and the cell surface
receptor responsible for retinol uptake called stimulated by
retinoic acid gene 6 [55].
At intermediate concentrations of ATRA, we consistently
observe an induction of UCP1 expression in mouse adipo-
cytes. This does not only occur in the mouse cells shown
here, but was also observed with WT-1 brown adipocytes
[56,57] and 3T3-F442A white adipocytes (data not shown).
Thus, our results demonstrate that ATRA can cause an
induction of UCP1 expression in white adipocyte cell
models of mouse origin. It is tempting to speculate thatexposure to ATRA will cause white preadipocytes and
mature adipocytes to transdifferentiate into brown-like
adipocytes in vitro. However, in order to confirm if a
transdifferentiation event has taken place in our study, a
more detailed gene expression analysis is required com-
bined with a characterization of mitochondrial function.
Using three cell models of human origin, SGBS and
hMADS cells as well as primary subcutaneous adipocytes
from two different donors, we failed to detect an induc-
tion of UCP1 expression by ATRA (see Figures 7 and 8).
hMADS cells have been proposed to represent brown or
brown-like adipocytes, the latter due to the induction of
UCP1 expression in response to prolonged culture in the
presence of rosiglitazone [58,59] or upon treatment with
atrial natriuretic peptide [60]. Despite being considered
white fat cells, SGBS and primary subcutaneous human
Figure 7 Chronic treatment with ATRA does not increase UCP1 expression in differentiating SGBS, hMADS and primary human
adipocytes. Total RNA was harvested at the indicated days (day 12 in panel A and B) and analyzed by RT-qPCR. Relative mRNA expression levels
of FABP4, UCP1 and RARβ were determined by normalization to TBP. ATRA was supplemented to differentiating SGBS cells (A), hMADS cells
(B) and primary human white preadipocytes (HPrAD) (C) from day −2 to day 12 at the concentrations indicated. (D) Protein levels of UCP1 with
GAPDH used as a loading control in SGBS and hMADS adipocytes. (A-C) Data represents mean + SEM (n = 3). *, p < 0.05 versus
vehicle-treated cells.
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in response to genetic manipulation [61,62]. Thus, the lack
of effect of ATRA in the human adipocyte models studied
here cannot be explained by an inherent inability to induce
expression of UCP1. Consistently, to our knowledge, an
induction of the endogenous human UCP1 gene by ATRA
has never been reported. Nevertheless, we cannot rule
out that the lack of response in our study is due to the
experimental setup or the human cell models used. In
particular, it remains to be shown if primary human
brown adipocytes respond to ATRA by increasing UCP1expression. However, as we consistently observe enhanced
expression of UCP1 by intermediate concentrations of
ATRA in mouse fat cells, we find this difference between
mouse and human adipocytes noteworthy.
Conclusions
In conclusion, we demonstrate that ATRA is a powerful
inducer of UCP1 expression in mouse white and brown
adipocytes, supporting that ATRA has the capacity to
increase the potential for uncoupled respiration in those
cells. The increased expression of UCP1 in response to
Figure 8 Acute exposure of mature human adipocytes to ATRA does not induce UCP1 expression. ATRA (1 μM) was supplemented to
mature SGBS adipocytes (A), hMADS adipocytes (B) and primary human white preadipocytes (HPrAD) (C) from day 12 and harvested after 24 h.
(D) Protein levels of UCP1 with GAPDH used as a loading control in SGBS and hMADS adipocytes. (A-C) Data represents mean + SEM (n = 3). *,
p < 0.05 versus vehicle-treated cells.
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pendent of PGC-1α. We do not find induction of UCP1
gene expression by ATRA in the human adipocytes studied
here, but whether this applies to the human UCP1 gene in
general remains to be determined. Nevertheless, differ-
ences between rodents and humans in terms of regulation
of UCP1 expression are highly relevant, as modulation of
BAT activity and browning of WAT are being considered
as potential anti-obesity targets. More studies comparing
rodent and human adipocytes are needed to understand
their similarities and differences with respect to regulation
of UCP1 expression.
Methods
Cell culture
WT and Rb−/− MEFs were propagated and differentiated
as previously described [56]. Immortalized PGC-1α+/+ andPGC-1α−/− brown preadipocyte cell lines were obtained
from Dr. Bruce M. Spiegelman [43], and C3H10T½ mes-
enchymal stem cells [36] and 3T3-L1 white preadipocytes
[63] were obtained from Dr. Karsten Kristiansen. Brown
preadipocyte cell lines and C3H10T½ cells were propa-
gated in Dulbecco’s Modified Eagle’s Medium (DMEM)
(Life Technologies) supplemented with 10% foetal bovine
serum (FBS) (Life Technologies) and differentiated as
WT and Rb−/− MEFs. 3T3-L1 cells were propagated in
DMEM supplemented with 10% bovine serum and differ-
entiated as WT and Rb−/− MEFs. Thus, all mouse cells
were cultured in the presence of rosiglitazone from day 0
until the time of harvesting. The SGBS white preadipocyte
cell line was obtained from Dr. Martin Wabitch [44] and
propagated in Advanced DMEM/F12 (Life Technologies)
with 10% FBS and 2 mM L-glutamine (Life Technologies).
Two days postconfluent cells (designated day 0) were
Murholm et al. BMC Cell Biology 2013, 14:41 Page 11 of 13
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FBS supplemented with 0.86 μM insulin (Roche), 1 μM
dexamethasone (Sigma-Aldrich), 0.5 mM 3-isobutyl-1-
methylxanthine (IBMX) (Sigma-Aldrich), 1 μM rosiglitazone
(Cayman Chemical), 1 μM cortisol (Sigma-Aldrich) and
1 nM 3,3′,5-triiodo-L-thyronine (T3) (Sigma-Aldrich). On
day 3 the cells were fed the same medium as on day 0. On
days 6, 9 and 12 medium contained 2% FBS, 0.86 μM
insulin, 1 μM rosiglitazone and 1 nM T3. hMADS cells
were obtained by Dr. Christian Dani and their propagation
and differentiation were carried out as described [45,46]
with minor modifications. Briefly, hMADS cells were
cultured in low glucose DMEM (Lonza) supplemented
with 10% FBS, 2 mM L-glutamine, 10 mM HEPES (Lonza)
and 2.5 ng/ml human fibroblast growth factor 2 (Life
Technologies). Two days postconfluent cells (designated
day 0) were induced to differentiate in low glucose
DMEM/Ham’s F12 medium (Lonza) with 10 mM HEPES,
2 mM L-glutamine supplemented with 10 μg/ml transfer-
rin, 0.86 μM insulin, 0.1 μM rosiglitazone, 0.2 nM T3,
1 μM dexamethasone and 0.5 mM IBMX. At days 2, 4, 6,
8, 10 and 12 medium was supplemented with 10 mM
HEPES, 2 mM L-glutamine, 10 μg/ml transferrin, 0.86 μM
insulin, 0.1 μM rosiglitazone and 0.2 nM T3. Primary hu-
man white subcutaneous preadipocytes (Lonza) were cul-
tured in PBM-2 medium (Lonza). Two days postconfluent
preadipocytes (designated day 0) were induced to differen-
tiate with PBM-2 medium supplemented with insulin,
dexamethasone, IBMX and indomethacin (all supplied by
Lonza) according to the instructions of the manufacturer.
On day 3 the cells were refed the same medium as on day
0. On days 6, 9 and 12 cells were refreshed with PBM-2
medium containing insulin and indomethacin. All media
described above were supplemented with 50 U/ml penicil-
lin and 50 μg/ml streptomycin, and all cells were cultured
at 37°C in humidified atmospheric air with 5% CO2, ex-
cept for hMADS cells that were cultured with 10% CO2.
Additional ligands were used in concentrations stated
in figures and figure legends and were added from either
day −2 and onwards in chronic treatment experiments
or from day 8 (mouse cells) or day 12 (human cells) in
experiments with acute exposure of mature adipocytes.
ATRA, TTNPB and AM580 were purchased from
Sigma-Aldrich. Tazarotene, CD1530 and BMS493 were
purchased from Tocris Bioscience, and GW501516 was
kindly provided by Novo Nordisk A/S. All nuclear recep-
tor ligands were dissolved in dimethyl sulfoxide (DMSO)
(Sigma-Aldrich), and dishes not supplemented with ligands
were treated with an equal volume of DMSO.
Reverse transcription-quantitative polymerase chain reaction
Total RNA was purified using TRI Reagent (Sigma-Aldrich).
Reverse transcription (RT) and RT-quantitative polymerase
chain reaction (RT-qPCR) were performed as previouslydescribed [56]. Primers used were: ADRP (mouse), fw-G
AATTTCTGGTTGGCACTGT, rev-GACCATTTCTCAG
CTCCACTC (80 bp); FABP4 (mouse), fw-TGGAAGCTT
GTCTCCAGTGA, rev-AATCCCCATTTACGCTGATG
(111 bp); RARβ (mouse), fw-ACAGATCTCCGCAGCAT
CAG, rev-GCATTGATCCAGGAATTTCCA (76 bp); TBP
(mouse), fw-ACCCTTCACCAATGACTCCTATG, rev-AT
GATGACTGCAGCAAATCGC (190 bp); UCP1 (mouse),
fw-GGCATTCAGAGGCAAATCAGCT, rev-CAATGAA
CACTGCCACACCTC (151 bp); FABP4 (human), fw-A
GCACCATAACCTTAGATGGGG, rev-CGTGGAAGTG
ACGCCTTTCA (132 bp); RARβ (human), fw-AAGTGC
TTTGAAGTGGGAATG, rev-GCTTTTCGGATCTTCT
CTGTG (143 bp); TBP (human), fw-CCCGAAACGCCG
AATATAA, rev-GAAAATCAGTGCCGTGGTTC (83 bp);
UCP1 (human), fw-CCAACTGTGCAATGAAAGTGT, rev-
CAAGTCGCAAGAAGGAAGGTA (81 bp).
Whole cell extracts and immunoblotting
Preparation of whole-cell extracts and immunoblotting
were done as described [64]. Antibodies used were against
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
(Ab8245, Abcam) and UCP1 (Ab10983, Abcam).
Statistical analysis
All experiments were repeated at least three times and
three dishes were harvested at each time point or treatment
for each independent experiment. Data from a representa-
tive experiment are presented as mean of the three dishes
(+SEM). Statistical significance was determined by Student’s
t-test. Bonferroni correction was applied when multiple
comparisons were carried out.
Abbreviations
ADRP: Adipose differentiation-related protein; ATRA: All-trans RA; BAT: Brown
adipose tissue; COUP-TFII: Chicken ovalbumin upstream promoter
transcription factor II; DMEM: Dulbecco’s Modified Eagle’s Medium;
FABP4: Fatty acid-binding protein 4; FBS: Foetal bovine serum;
GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; HPrAD: Primary human
white preadipocytes/adipocytes; IBMX: 3-isobutyl-1-methylxanthine;
MAPK: Mitogen activated protein kinase; MEF: Mouse embryo fibroblast;
PGC-1α: PPARγ coactivator-1α; PPAR: Peroxisome proliferator-activated
receptor; RA: Retinoic acid; RAR: RA receptor; Rb: Retinoblastoma gene;
RT-qPCR: Reverse transcription-quantitative polymerase chain reaction; T3:
3,3′,5-triiodo-L-thyronine; TBP: TATA-binding protein; TR4: Testicular orphan
receptor 4; UCP1: Uncoupling protein 1; WAT: White adipose tissue;
WT: Wild-type.
Competing interest
The authors declare that they have no competing interests.
Authors’ contributions
MM, MSI, BQ and JBH conceived and designed the experiments. MM, MSI,
ALB, SW, CS, JSP, MMN and ASH performed the experiments. All authors
analyzed and interpreted the data. MSI prepared the figures. MM, MSI and
JBH wrote the paper. All authors read and approved the final manuscript.
Acknowledgements
We appreciate the generous gift of reagents from Drs. Bruce M. Spiegelman
(Harvard Medical School, Dana Farber Cancer Institute, Boston, USA), Martin
Wabitch (University of Ulm, Germany), Christian Dani (University of Nice
Murholm et al. BMC Cell Biology 2013, 14:41 Page 12 of 13
http://www.biomedcentral.com/1471-2121/14/41Sophia Antipolis, France), Karsten Kristiansen (University of Copenhagen,
Denmark) and Novo Nordisk A/S (Måløv, Denmark). Sally Winther is the
recipient of a Novo Scholarship. This work was supported by grants to Jacob
B. Hansen from the EU FP7 project DIABAT (HEALTH-F2-2011-278373), The
Danish Medical Research Council, The Novo Nordisk Foundation, The
Carlsberg Foundation, The Aase and Ejnar Danielsen Foundation, The
Augustinus Foundation, The Hartmann Brothers’ Foundation, The Beckett
Foundation and Fonden til Laegevidenskabens Fremme.
Author details
1Department of Biology, University of Copenhagen, Universitetsparken 13,
DK-2100 Copenhagen Ø, Denmark. 2Department of Biomedical Sciences,
University of Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen N,
Denmark.
Received: 1 May 2013 Accepted: 18 September 2013
Published: 23 September 2013References
1. Cannon B, Nedergaard J: Brown adipose tissue: function and
physiological significance. Physiol Rev 2004, 84(1):277–359.
2. Nedergaard J, Bengtsson T, Cannon B: Unexpected evidence for active
brown adipose tissue in adult humans. Am J Physiol Endocrinol Metab
2007, 293(2):E444–E452.
3. Cousin B, Cinti S, Morroni M, Raimbault S, Ricquier D, Penicaud L, Casteilla L:
Occurrence of brown adipocytes in rat white adipose tissue: molecular
and morphological characterization. J Cell Sci 1992, 103(Pt 4):931–942.
4. Himms-Hagen J, Cui J, Danforth E Jr, Taatjes DJ, Lang SS, Waters BL, Claus
TH: Effect of CL-316,243, a thermogenic beta 3-agonist, on energy
balance and brown and white adipose tissues in rats. Am J Physiol 1994,
266(4 Pt 2):R1371–R1382.
5. Nedergaard J, Bengtsson T, Cannon B: Three years with adult human
brown adipose tissue. Ann NY Acad Sci 2010, 1212:E20–E36.
6. Oberkofler H, Dallinger G, Liu YM, Hell E, Krempler F, Patsch W: Uncoupling
protein gene: quantification of expression levels in adipose tissues of
obese and non-obese humans. J Lipid Res 1997, 38(10):2125–2133.
7. Yang X, Enerback S, Smith U: Reduced expression of FOXC2 and brown
adipogenic genes in human subjects with insulin resistance. Obes Res
2003, 11(10):1182–1191.
8. Semple RK, Crowley VC, Sewter CP, Laudes M, Christodoulides C, Considine
RV, Vidal-Puig A, O’Rahilly S: Expression of the thermogenic nuclear
hormone receptor coactivator PGC-1alpha is reduced in the adipose
tissue of morbidly obese subjects. Int J Obes Relat Metab Disord 2004,
28(1):176–179.
9. Chambon P: A decade of molecular biology of retinoic acid receptors.
Faseb J 1996, 10(9):940–954.
10. Evans TR, Kaye SB: Retinoids: present role and future potential. Br J Cancer
1999, 80(1–2):1–8.
11. Petkovich M, Brand NJ, Krust A, Chambon P: A human retinoic acid
receptor which belongs to the family of nuclear receptors. Nature 1987,
330(6147):444–450.
12. Giguere V, Ong ES, Segui P, Evans RM: Identification of a receptor for the
morphogen retinoic acid. Nature 1987, 330(6149):624–629.
13. Shaw N, Elholm M, Noy N: Retinoic acid is a high affinity selective ligand
for the peroxisome proliferator-activated receptor beta/delta. J Biol Chem
2003, 278(43):41589–41592.
14. Zhou XE, Suino-Powell KM, Xu Y, Chan CW, Tanabe O, Kruse SW, Reynolds R,
Engel JD, Xu HE: The orphan nuclear receptor TR4 is a vitamin A-activated
nuclear receptor. J Biol Chem 2011, 286(4):2877–2885.
15. Kruse SW, Suino-Powell K, Zhou XE, Kretschman JE, Reynolds R, Vonrhein C,
Xu Y, Wang L, Tsai SY, Tsai MJ, et al: Identification of COUP-TFII orphan
nuclear receptor as a retinoic acid-activated receptor. PLoS Biol 2008,
6(9):e227.
16. Berry DC, Noy N: All-trans-retinoic acid represses obesity and insulin
resistance by activating both peroxisome proliferation-activated receptor
beta/delta and retinoic acid receptor. Mol Cell Biol 2009, 29(12):3286–3296.
17. Bonet ML, Oliver J, Pico C, Felipe F, Ribot J, Cinti S, Palou A: Opposite
effects of feeding a vitamin A-deficient diet and retinoic acid treatment
on brown adipose tissue uncoupling protein 1 (UCP1), UCP2 and leptin
expression. J Endocrinol 2000, 166(3):511–517.18. Bastien J, Rochette-Egly C: Nuclear retinoid receptors and the
transcription of retinoid-target genes. Gene 2004, 328:1–16.
19. Schwarz EJ, Reginato MJ, Shao D, Krakow SL, Lazar MA: Retinoic acid blocks
adipogenesis by inhibiting C/EBPbeta-mediated transcription. Mol Cell
Biol 1997, 17(3):1552–1561.
20. Xue JC, Schwarz EJ, Chawla A, Lazar MA: Distinct stages in adipogenesis
revealed by retinoid inhibition of differentiation after induction of
PPARgamma. Mol Cell Biol 1996, 16(4):1567–1575.
21. Berry DC, DeSantis D, Soltanian H, Croniger CM, Noy N: Retinoic acid
upregulates preadipocyte genes to block adipogenesis and suppress
diet-induced obesity. Diabetes 2012, 61(5):1112–1121.
22. Safonova I, Reichert U, Shroot B, Ailhaud G, Grimaldi P: Fatty acids and
retinoids act synergistically on adipose cell differentiation. Biochem
Biophys Res Commun 1994, 204(2):498–504.
23. Marchildon F, St-Louis C, Akter R, Roodman V, Wiper-Bergeron NL:
Transcription factor Smad3 is required for the inhibition of adipogenesis
by retinoic acid. J Biol Chem 2010, 285(17):13274–13284.
24. Alvarez R, de Andres J, Yubero P, Vinas O, Mampel T, Iglesias R, Giralt M,
Villarroya F: A novel regulatory pathway of brown fat thermogenesis.
Retinoic acid is a transcriptional activator of the mitochondrial
uncoupling protein gene. J Biol Chem 1995, 270(10):5666–5673.
25. Rabelo R, Reyes C, Schifman A, Silva JE: A complex retinoic acid response
element in the uncoupling protein gene defines a novel role for
retinoids in thermogenesis. Endocrinology 1996, 137(8):3488–3496.
26. Sears IB, MacGinnitie MA, Kovacs LG, Graves RA: Differentiation-dependent
expression of the brown adipocyte uncoupling protein gene: regulation
by peroxisome proliferator-activated receptor gamma. Mol Cell Biol 1996,
16(7):3410–3419.
27. del Mar Gonzalez-Barroso M, Pecqueur C, Gelly C, Sanchis D, Alves-Guerra
MC, Bouillaud F, Ricquier D, Cassard-Doulcier AM: Transcriptional activation
of the human ucp1 gene in a rodent cell line. Synergism of retinoids,
isoproterenol, and thiazolidinedione is mediated by a multipartite
response element. J Biol Chem 2000, 275(41):31722–31732.
28. Puigserver P, Vazquez F, Bonet ML, Pico C, Palou A: In vitro and in vivo
induction of brown adipocyte uncoupling protein (thermogenin) by
retinoic acid. Biochem J 1996, 317(Pt 3):827–833.
29. Teruel T, Hernandez R, Benito M, Lorenzo M: Rosiglitazone and retinoic
acid induce uncoupling protein-1 (UCP-1) in a p38 mitogen-activated
protein kinase-dependent manner in fetal primary brown adipocytes.
J Biol Chem 2003, 278(1):263–269.
30. Mercader J, Madsen L, Felipe F, Palou A, Kristiansen K, Bonet ML: All-trans
retinoic acid increases oxidative metabolism in mature adipocytes.
Cell Physiol Biochem 2007, 20(6):1061–1072.
31. Mercader J, Palou A, Bonet ML: Induction of uncoupling protein-1 in
mouse embryonic fibroblast-derived adipocytes by retinoic acid. Obesity
(Silver Spring) 2010, 18(4):655–662.
32. Mercader J, Ribot J, Murano I, Felipe F, Cinti S, Bonet ML, Palou A:
Remodeling of white adipose tissue after retinoic acid administration in
mice. Endocrinology 2006, 147(11):5325–5332.
33. de The H, Marchio A, Tiollais P, Dejean A: Differential expression and
ligand regulation of the retinoic acid receptor alpha and beta genes.
Embo J 1989, 8(2):429–433.
34. Martin CA, Ziegler LM, Napoli JL: Retinoic acid, dibutyryl-cAMP, and
differentiation affect the expression of retinoic acid receptors in F9 cells.
Proc Natl Acad Sci USA 1990, 87(12):4804–4808.
35. Hansen JB, Jorgensen C, Petersen RK, Hallenborg P, De Matteis R, Boye HA,
Petrovic N, Enerback S, Nedergaard J, Cinti S, et al: Retinoblastoma protein
functions as a molecular switch determining white versus brown adipocyte
differentiation. Proc Natl Acad Sci USA 2004, 101(12):4112–4117.
36. Reznikoff CA, Brankow DW, Heidelberger C: Establishment and
characterization of a cloned line of C3H mouse embryo cells sensitive to
postconfluence inhibition of division. Cancer Res 1973, 33(12):3231–3238.
37. Charton J, Deprez-Poulain R, Hennuyer N, Tailleux A, Staels B, Deprez B:
Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives.
Bioorg Med Chem Lett 2009, 19(2):489–492.
38. Schug TT, Berry DC, Shaw NS, Travis SN, Noy N: Opposing effects of
retinoic acid on cell growth result from alternate activation of two
different nuclear receptors. Cell 2007, 129(4):723–733.
39. Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM: Peroxisome-
proliferator-activated receptor delta activates fat metabolism to prevent
obesity. Cell 2003, 113(2):159–170.
Murholm et al. BMC Cell Biology 2013, 14:41 Page 13 of 13
http://www.biomedcentral.com/1471-2121/14/4140. Pan D, Fujimoto M, Lopes A, Wang YX: Twist-1 is a PPARdelta-inducible,
negative-feedback regulator of PGC-1alpha in brown fat metabolism.
Cell 2009, 137(1):73–86.
41. Vosper H, Patel L, Graham TL, Khoudoli GA, Hill A, Macphee CH, Pinto I,
Smith SA, Suckling KE, Wolf CR, et al: The peroxisome proliferator-
activated receptor delta promotes lipid accumulation in human
macrophages. J Biol Chem 2001, 276(47):44258–44265.
42. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM: A
cold-inducible coactivator of nuclear receptors linked to adaptive
thermogenesis. Cell 1998, 92(6):829–839.
43. Uldry M, Yang W, St-Pierre J, Lin J, Seale P, Spiegelman BM:
Complementary action of the PGC-1 coactivators in mitochondrial
biogenesis and brown fat differentiation. Cell Metab 2006, 3(5):333–341.
44. Wabitsch M, Brenner RE, Melzner I, Braun M, Moller P, Heinze E, Debatin KM,
Hauner H: Characterization of a human preadipocyte cell strain with high
capacity for adipose differentiation. Int J Obes Relat Metab Disord 2001,
25(1):8–15.
45. Rodriguez AM, Pisani D, Dechesne CA, Turc-Carel C, Kurzenne JY,
Wdziekonski B, Villageois A, Bagnis C, Breittmayer JP, Groux H, et al:
Transplantation of a multipotent cell population from human adipose
tissue induces dystrophin expression in the immunocompetent mdx
mouse. J Exp Med 2005, 201(9):1397–1405.
46. Zaragosi LE, Ailhaud G, Dani C: Autocrine fibroblast growth factor 2
signaling is critical for self-renewal of human multipotent adipose-
derived stem cells. Stem Cells 2006, 24(11):2412–2419.
47. Villarroya F, Giralt M, Iglesias R: Retinoids and adipose tissues: metabolism,
cell differentiation and gene expression. Int J Obes Relat Metab Disord
1999, 23(1):1–6.
48. Bonet ML, Ribot J, Palou A: Lipid metabolism in mammalian tissues and
its control by retinoic acid. Biochim Biophys Acta 2012, 1821(1):177–189.
49. Ribot J, Felipe F, Bonet ML, Palou A: Retinoic acid administration and
vitamin A status modulate retinoid X receptor alpha and retinoic acid
receptor alpha levels in mouse brown adipose tissue. Mol Cell Biochem
2004, 266(1–2):25–30.
50. Kumar MV, Scarpace PJ: Differential effects of retinoic acid on uncoupling
protein-1 and leptin gene expression. J Endocrinol 1998, 157(2):237–243.
51. Larose M, Cassard-Doulcier AM, Fleury C, Serra F, Champigny O, Bouillaud F,
Ricquier D: Essential cis-acting elements in rat uncoupling protein gene
are in an enhancer containing a complex retinoic acid response domain.
J Biol Chem 1996, 271(49):31533–31542.
52. Alvarez R, Checa M, Brun S, Vinas O, Mampel T, Iglesias R, Giralt M, Villarroya
F: Both retinoic-acid-receptor- and retinoid-X-receptor-dependent
signalling pathways mediate the induction of the brown-adipose-tissue-
uncoupling-protein-1 gene by retinoids. Biochem J 2000, 345(Pt 1):91–97.
53. Hernandez A, de Mena RM, Martin E, Obregon MJ: Differences in the response
of UCP1 mRNA to hormonal stimulation between rat and mouse primary
cultures of brown adipocytes. Cell Physiol Biochem 2011, 28(5):969–980.
54. Lehr L, Canola K, Leger B, Giacobino JP: Differentiation and
characterization in primary culture of white adipose tissue brown
adipocyte-like cells. Int J Obes (Lond) 2009, 33(6):680–686.
55. Berry DC, Noy N: Signaling by vitamin A and retinol-binding protein in
regulation of insulin responses and lipid homeostasis. Biochim Biophys
Acta 2012, 1821(1):168–176.
56. Murholm M, Dixen K, Qvortrup K, Hansen LH, Amri EZ, Madsen L, Barbatelli
G, Quistorff B, Hansen JB: Dynamic regulation of genes involved in
mitochondrial DNA replication and transcription during mouse brown
fat cell differentiation and recruitment. PLoS One 2009, 4(12):e8458.
57. Murholm M, Dixen K, Hansen JB: Ras signalling regulates differentiation
and UCP1 expression in models of brown adipogenesis. Biochim Biophys
Acta 2010, 1800(6):619–627.
58. Elabd C, Chiellini C, Carmona M, Galitzky J, Cochet O, Petersen R, Penicaud
L, Kristiansen K, Bouloumie A, Casteilla L, et al: Human multipotent
adipose-derived stem cells differentiate into functional brown
adipocytes. Stem cells 2009, 27(11):2753–2760.
59. Pisani DF, Djedaini M, Beranger GE, Elabd C, Scheideler M, Ailhaud G, Amri
EZ: Differentiation of human adipose-derived stem cells into “Brite”
(brown-in-white) adipocytes. Frontiers Endocrinol 2011, 2:87.
60. Bordicchia M, Liu D, Amri EZ, Ailhaud G, Dessi-Fulgheri P, Zhang C,
Takahashi N, Sarzani R, Collins S: Cardiac natriuretic peptides act via p38
MAPK to induce the brown fat thermogenic program in mouse and
human adipocytes. J Clin Investig 2012, 122(3):1022–1036.61. Tews D, Fischer-Posovszky P, Fromme T, Klingenspor M, Fischer J, Ruther U,
Marienfeld R, Barth T, Moller P, Debatin K, et al: FTO deficiency induces
UCP-1 expression and mitochondrial uncoupling in adipocytes.
Endocrinology 2013, 154(9):3141–3151.
62. Tiraby C, Tavernier G, Lefort C, Larrouy D, Bouillaud F, Ricquier D, Langin D:
Acquirement of brown fat cell features by human white adipocytes.
J Biol Chem 2003, 278(35):33370–33376.
63. Green HKO: Sublines of mouse 3T3 cells that accumulate lipid. Cell 1974,
1:113–116.
64. Hansen JB, Petersen RK, Larsen BM, Bartkova J, Alsner J, Kristiansen K:
Activation of peroxisome proliferator-activated receptor gamma
bypasses the function of the retinoblastoma protein in adipocyte
differentiation. J Biol Chem 1999, 274(4):2386–2393.
doi:10.1186/1471-2121-14-41
Cite this article as: Murholm et al.: Retinoic acid has different effects on
UCP1 expression in mouse and human adipocytes. BMC Cell Biology
2013 14:41.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
